Please login to the form below

Not currently logged in
Email:
Password:

Calquence

This page shows the latest Calquence news and features for those working in and with pharma, biotech and healthcare.

AZ’s BTK inhibitor Calquence fails in COVID-19 study

AZ’s BTK inhibitor Calquence fails in COVID-19 study

AstraZenea’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence has failed to improve survival and prevent respiratory failure in hospitalised COVID-19 patients. ... In a statement, AZ said that the results from the CALAVI trial do not impact the

Latest news

More from news
Approximately 6 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...